The imaging technology at the heart of the study is prostate-specific membrane antigen positron emission tomography, usually abbreviated PSMA PET. Unlike conventional CT or bone scans, which rely on anatomical changes to reveal tumours, PSMA PET exploits the fact that prostate cancer cells overproduce a surface protein called prostate-specific membrane antigen. A radioactive tracer, either gallium-68 labelled PSMA-11 or fluorine-18 labelled PSMA-1007 in this study, is injected into the bloodstream and binds to that protein, making even small clusters of cancer cells glow on the scan. In this cohort, scans were performed roughly an hour after tracer injection and jointly reviewed by an experienced nuclear medicine physician and a radiologist, with lesion locations confirmed on the accompanying CT component. This sensitivity allows detection of nodal recurrence at prostate-specific antigen, or PSA, levels far below those at which older imaging modalities become useful, opening a therapeutic window in which disease is still limited and potentially curable.

Armed with this detailed map of where the cancer had returned, the treating radiation oncologists did something that has become increasingly evidence-supported but had lacked long-term real-world validation: they delivered elective nodal radiotherapy, or ENRT. Rather than irradiating only the few lymph nodes visible on the PET scan, a strategy known as metastasis-directed therapy, ENRT treats the entire lymphatic drainage region at risk, including nodes that may harbour microscopic disease invisible to even the most sensitive scanner. Target volumes followed the Radiation Therapy Oncology Group atlas and, from 2020 onwards, the NRG Oncology consensus guidelines, adjusted according to the PSMA PET findings. In patients with disease extending above the pelvis, the elective field was stretched to include the paraaortic lymphatic pathways up to two centimetres above the highest PET-positive node. The prostate bed was routinely included in the treatment volume for patients who had not previously been irradiated there.

The technical execution reflected modern image-guided practice. In Innsbruck, patients initially received three-dimensional conformal radiotherapy before the centre switched to volumetric modulated arc therapy in 2017, while Munich used intensity-modulated or volumetric modulated arc therapy throughout. Daily or near-daily cone-beam CT verified patient positioning. All plans included a simultaneous integrated boost, meaning PET-positive lymph nodes received a higher radiation dose per fraction than the surrounding elective regions. In dose terms normalised to two-Gy fractions, the elective nodal regions received a median of 47.5 Gy, the prostate bed 66.0 Gy, locally recurrent disease 70.0 Gy, and PET-positive lymph nodes a median of 62.3 Gy, with doses adapted to respect the tolerance of nearby organs such as the bowel and bladder. Androgen deprivation therapy, which suppresses the testosterone that fuels prostate cancer growth, was recommended for all patients for 24 to 36 months and was actually given to 83.8 percent of the cohort.

The headline result is that this approach delivers durable disease control in routine clinical practice, not just in the carefully selected populations of clinical trials. Across the whole cohort, the five-year metastasis-free survival rate was 61.2 percent, meaning nearly two-thirds of these men remained free of distant spread five years after treatment. Biochemical progression-free survival, which tracks whether PSA remains suppressed, stood at 56.4 percent at five years, and overall survival reached 90.6 percent. Only 20 of the 179 patients died during follow-up, and just three of those had documented metastatic prostate cancer before death. For a population with nodal recurrence after prostatectomy, many of whom carried high-risk features such as grade 4 or 5 tumours, positive surgical margins, or disease extending beyond the pelvis, these figures represent a meaningful benchmark.

The most striking numbers emerged when the researchers separated two biologically distinct groups that are often lumped together. Some men experience a true biochemical recurrence, meaning their PSA fell to undetectable levels after surgery and only later began to rise. Others have PSA persistence, in which the marker never cleared after the operation, a sign that occult cancer cells were likely already disseminated at the time of surgery. Among the 104 men with true recurrence, five-year metastasis-free survival reached 74.3 percent and biochemical progression-free survival 62.3 percent, figures that closely approach the results of the randomised PEACE V-STORM trial, which reported four-year metastasis-free survival of 76 percent for elective nodal radiotherapy. By contrast, PSA persistence independently predicted worse outcomes in multivariable analysis, with more than double the risk of metastasis or death and nearly double the risk of biochemical progression, consistent with the idea that persistence marks more advanced, systemic disease.

The role of hormone therapy emerged as the other dominant prognostic factor. Men who received androgen deprivation therapy alongside their radiotherapy had a 64 percent lower risk of distant metastasis or death and a 74 percent lower risk of biochemical progression compared with those who did not, effect sizes that exceed those reported in meta-analyses of postoperative radiotherapy. The authors caution that this observational association cannot prove causation and may partly reflect the higher disease burden in patients with PET-detected nodal metastases, in whom combined modality treatment may simply be necessary. They also deliberately avoided analysing hormone therapy duration, because retrospectively grouping patients by the therapy actually completed rather than the intended duration invites statistical distortions known as immortal-time bias. The optimal duration of androgen suppression in this setting remains an open question for prospective trials.

Perhaps the most instructive finding concerns where the cancer returned when it did return. Among the 54 patients with imaging-confirmed recurrence, only 7.4 percent failed within the irradiated field, while 72.2 percent relapsed exclusively outside it and another 20.4 percent relapsed both inside and outside. This spatial pattern carries a double message. On one hand, it suggests the radiation targets were well designed, since true in-field failure was rare. On the other hand, the overwhelming predominance of out-of-field and distant relapse, including bone metastases in 20.7 percent of the entire cohort, points to microscopic disease lurking below the detection threshold of even PSMA PET, or to an inherently more aggressive systemic biology in these tumours. A negative PSMA PET scan, in other words, does not guarantee the absence of occult metastases, particularly in patients with high PSA levels at recurrence, and the authors argue that this limitation, not inadequate target coverage, is the main enemy to be fought.

The study is not without caveats, and the authors are candid about them. Its retrospective design introduces selection bias and limits causal inference, treatment varied between centres and eras, and the two institutions used different tracers and imaging protocols. Most importantly, toxicity was not systematically assessed and patient-reported quality of life was not collected, so the tolerability of this intensive combined approach cannot be reliably judged from these data. The multivariable models, built on data-driven variable selection, should be treated as exploratory. Nevertheless, the inclusion of higher-risk, less selected patients, including those with PSA persistence and paraaortic disease that the PEACE V-STORM trial excluded, is precisely what makes the results valuable as a real-world benchmark. Two ongoing phase III trials, GETUG-P12-OLIGOPELVIS 2 and POINTER-PC, are now testing whether adding elective nodal radiotherapy to hormone therapy improves survival and whether treating whole nodal regions outperforms targeting only visible nodes. Until those results mature, this bi-institutional analysis provides the strongest long-term signal yet that PSMA PET-guided elective nodal radiotherapy, combined with androgen deprivation, can convert nodal recurrence after prostatectomy from an ominous harbinger of metastatic disease into a controllable, and for many patients durably arrested, chapter of the illness.

Subject of Research: Long-term outcomes of PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal prostate cancer recurrence after radical prostatectomy

Article Title: PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis

Article References: Vorbach, S. M., Seppi, T., Santo, G., Virgolini, I., Ganswindt, U., Keilholz, M., Brose, S. F., Casuscelli, J., Klimek, K., Werner, R. A., Schmidt-Hegemann, N.-S., Belka, C., Trapp, C., & Rogowski, P. (2026). PSMA PET/CT-guided salvage elective nodal radiotherapy for nodal metastases after radical prostatectomy: a bi-institutional long-term outcome analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08147-z

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08147-z

Keywords: PSMA PET/CT, prostate cancer, elective nodal radiotherapy, radical prostatectomy, nodal metastases, salvage radiotherapy, androgen deprivation therapy, metastasis-free survival, biochemical recurrence, oligorecurrent disease, radiation oncology, molecular imaging

The study, conducted at BG University Hospital Bergmannsheil in Bochum and published in the Journal of Cancer Research and Clinical Oncology, followed 59 consecutive patients with histologically confirmed synovial sarcoma of the extremities treated over a 24-year period between 2000 and 2023. Of these, 23 tumors arose in the upper extremity and 36 in the lower extremity. The researchers set out with a deceptively simple question: does the limb in which the tumor sits influence the surgical pathway and the postoperative course, or is location merely a bystander variable with no practical consequence? Their findings suggest the answer is far from trivial.

The co-primary endpoints of the analysis were the presence of a microscopically positive margin, designated R1, at the initial resection, and any postoperative complication within eight weeks of surgery, graded according to the widely used Clavien–Dindo classification. Margin status is a cornerstone of sarcoma surgery because residual microscopic disease at the cut edge is associated with local recurrence and, in many series, with diminished survival. Achieving an R0 resection—complete removal with microscopically clear margins—is the explicit goal of every limb-sparing sarcoma operation.

What the team found was a striking asymmetry between the two anatomical groups. Positive margins at the index operation were recorded in 14 of 23 upper-extremity patients, or 61 percent, compared with only 5 of 36 lower-extremity patients, or 14 percent. Expressed as an odds ratio, upper-extremity tumors carried a nearly tenfold higher likelihood of an R1 margin at the first surgery, at 9.64 with a 95 percent confidence interval of 2.73 to 34.1 and a P value below 0.001. Neoadjuvant therapy, given before surgery to shrink the tumor, was also far more common in the upper-extremity group, at 39 percent versus 8 percent, a difference that reached statistical significance with P equal to 0.007.

The authors interpret this pattern as a reflection of surgical anatomy rather than of biology. The arm and hand are crowded, functionally dense territories. Vital nerves, vessels and tendons course through narrow compartments, and resecting a sarcoma with a wide cuff of healthy tissue—the standard for sarcoma surgery—often collides with the imperative to preserve hand and arm function. In the forearm and wrist, where critical structures lie millimeters beneath the skin, achieving a clear margin may be anatomically impossible without sacrificing essential function. The leg, by contrast, offers more expansive soft-tissue envelopes, particularly in the thigh, where wide resections can be accommodated with less functional penalty. This anatomical headroom appears to translate into cleaner first-pass margins.

Yet the trade-off ran in the opposite direction when the researchers examined complications. Any postoperative complication within eight weeks occurred in only 13 percent of upper-extremity patients but in 53 percent of lower-extremity patients, yielding an odds ratio of 0.13 for upper-extremity surgery relative to lower-extremity surgery, with a 95 percent confidence interval of 0.03 to 0.53 and P equal to 0.002. Major complications, the more severe grades of the Clavien–Dindo scale, followed the same trend, affecting 9 percent of upper-extremity patients and 39 percent of lower-extremity patients, with P equal to 0.015. Lower-extremity sarcoma surgery, typically involving larger resections, more extensive reconstruction, and the hemodynamic and wound-healing stresses of the leg, clearly extracts a heavier early toll.

Reconstructive strategy also diverged between the two groups. Tumors of the leg, particularly after wide resections, frequently demanded flap coverage, skin grafts and other reconstructive procedures to close large soft-tissue defects, whereas upper-extremity cases more often required staged or secondary procedures, including planned re-excision to secure clear margins after an initial R1 result. Importantly, the study found that definitive R0 resection was ultimately achieved in all patients. Even when the first operation in an upper-extremity case left microscopic disease behind, re-excision successfully converted the margin status. The message is one of cautious reassurance: the anatomical disadvantage of the arm is real, but it is surgically recoverable through vigilant follow-up and willingness to operate again.

The oncological outcomes add another layer of nuance. Seven of the nine distant metastases observed in the cohort occurred in patients with lower-extremity tumors, and several of these events emerged beyond six years after treatment, underscoring synovial sarcoma’s reputation as a late-relapsing disease. Ten-year metastasis-free survival was 90 percent in the upper-extremity group versus 56 percent in the lower-extremity group. Because the study was single-center, retrospective and modest in size, the authors deliberately classified these time-to-event findings as exploratory; the log-rank comparison yielded a P value of 0.095, which does not meet conventional thresholds of statistical significance. Still, the direction of the difference aligns with the larger tumor volumes and deeper compartments often seen in leg sarcomas, and the long tail of metastatic risk serves as a sobering reminder that synovial sarcoma follow-up must extend well beyond the five-year mark commonly used for many other cancers.

Methodologically, the study draws on a rigorous institutional registry. Screening of 1,060 registry entries from January 2000 to December 2023 identified the 59 surgically treated extremity synovial sarcomas after exclusion of entries that failed histological or anatomical eligibility criteria. Statistical analysis employed Fisher exact tests and the Mann–Whitney U test for group comparisons, and Kaplan–Meier curves with log-rank tests for survival endpoints. The researchers were careful to frame their conclusions within the limits of the design: this was a retrospective single-center cohort, and the exploratory survival findings require multicenter validation before they can inform practice guidelines. The study was conducted in line with the Declaration of Helsinki, with ethics approval from Ruhr University Bochum and written informed consent from all participants.

The clinical implications are nonetheless compelling. If upper-extremity synovial sarcomas systematically arrive at the operating table with a higher risk of positive margins, then surgical planning for these tumors should anticipate the need for neoadjuvant therapy and planned re-excision from the outset, rather than treating a positive margin as a surprise. Conversely, the high complication burden of lower-extremity surgery argues for intensified perioperative care, aggressive wound surveillance and perhaps earlier mobilization protocols in these patients. Above all, the study reframes anatomical location as an actionable variable in sarcoma care rather than a descriptive footnote. For a disease in which a single millimeter of residual tissue can set the stage for recurrence years later, understanding how the body’s own geography constrains the surgeon’s knife may prove as important as any drug in the oncological arsenal.

Subject of Research: Upper- versus lower-extremity synovial sarcoma: surgical margins, postoperative morbidity and long-term outcomes in a 24-year cohort

Article Title: Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort

Article References: Weskamp, P., Drysch, M., Fiedler, A., Schmidt, S. V., Reinkemeier, F., Steubing, Y., Lehnhardt, M., Dadras, M., Puscz, F., & Wallner, C. (2026). Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort. Journal of Cancer Research and Clinical Oncology, 152(9), Article 181. https://doi.org/10.1007/s00432-026-06619-1

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06619-1

Keywords: synovial sarcoma, soft-tissue sarcoma, surgical margins, R1 resection, re-excision, postoperative complications, Clavien–Dindo, neoadjuvant therapy, metastasis-free survival, reconstruction, surgical oncology, extremity tumors